This study investigates neoadjuvant triple therapy for patients with resectable pancreatic cancer. The purpose of this study is to see if this approach can improve outcomes for these patients.
The study evaluates the safety and effectiveness of combining chemotherapy, immunotherapy, and radiotherapy before surgery. It looks at whether this combination can improve survival rates for patients with resectable pancreatic cancer.
- Who can participate: Adults aged 18 and older with confirmed pancreatic adenocarcinoma that is resectable or borderline resectable can participate. Key eligibility includes a good performance status and the ability to undergo multiple treatments. Participants with metastatic or locally advanced pancreatic cancer are not eligible.
- Study details: Participants will receive chemotherapy, immunotherapy, and radiotherapy before surgery.
How understandable was the trial content above?
Hard to understand
Easy to understand